In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Advent International enters agreements to buy Zentiva from Sanofi for €1.9bn; deal closes

Executive Summary

Sanofi confirmed that is in exclusive negotiations to divest its European generics business Zentiva BV to private equity firm Advent International for €1.9bn ($2.3bn). The deal is said to be binding and fully financed, and could close by the end of year, pending definitive agreements and regulatory approval.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Divestiture/Spin-Out
    • Full Acquisition
    • Payment Includes Cash

Related Companies